1,317
Total Claims
$6.8M
Drug Cost
202
Beneficiaries
$33K
Cost/Patient
Risk Score Breakdown 6/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+6
Score components are additive. Read full methodology
Peer Comparison vs. 3,372 Medical Oncology providers
+166%
Opioid rate vs peers
15.6% vs 5.9% avg
+174%
Cost per patient vs peers
$33K vs $12K avg
Opioid Prescribing
15.6%
Opioid Rate
205
Opioid Claims
$5,182
Opioid Cost
24.4%
Long-Acting Rate
Brand vs Generic
100% generic
Brand: 0 claims · $0
Generic: 794 claims · $269K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Lenalidomide | 177 | $3.4M |
| Pomalidomide | 40 | $988K |
| Ibrutinib | 41 | $696K |
| Acalabrutinib Maleate | 22 | $330K |
| Lenalidomide | 12 | $239K |
| Ruxolitinib Phosphate | 13 | $235K |
| Venetoclax | 16 | $205K |
| Apixaban | 70 | $66K |
| Rivaroxaban | 53 | $48K |
| Dabigatran Etexilate Mesylate | 28 | $9,827 |
| Hydroxyurea | 71 | $2,413 |
| Oxycodone Hcl/Acetaminophen | 73 | $2,031 |
| Dexamethasone | 131 | $1,584 |
| Morphine Sulfate | 44 | $1,426 |
| Acyclovir | 38 | $853 |
Prescribing Profile
Patient Profile
70
Avg Age
49%
Female
2.42
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About